On the morning of the 31st, a Volatility Intervention (VI) was triggered for HLB Pharma. Notably, a dynamic VI was activated on the NXT market. The dynamic disparity rate was -6.36, and the trigger price was 7,940 won.

HLB Pharma previously reached its daily upper limit on July 15, but has since failed to sustain its upward momentum. However, the fact that the stock rebounded after declining the previous day (the 30th) is worth evaluating positively.

Meanwhile, HLB's subsidiary, Immunomic Therapeutics, announced on the 31st that it has commenced the first patient dosing in the U.S. Phase 1 clinical trial of 'ITI-5000,' a candidate for a cancer treatment vaccine targeting triple-negative breast cancer. According to Immunomic, the dosing phase began on the 16th at a U.S. clinical institution.

ITI-5000 is a cancer vaccine candidate based on 'UNITE,' an immunotherapy vaccine platform independently developed by Immunomic, which incorporates self-amplifying RNA (saRNA) technology.

At this juncture, it is necessary to closely examine how major positive news from group companies impacts the stock prices of their affiliates. One must also always keep in mind that there are many variables within the market.

[This article was written for informational purposes and does not constitute investment advice or a recommendation to buy or sell any specific stock. High volatility may occur due to changes in supply and demand. The final decision and responsibility for investments lie with the investor.]